RecruitingPhase 3Phase 4ACTRN12608000237381

Detection of exogenous insulin in blood and urine in type I diabetics and non diabetics.

Detection of exogenous insulin (in blood and urine) as a doping agent in 6 type I diabetics and 6 non diabetics, both male and female, aged 18 to 45. An open label cross over study.

Sponsor

Concord Repatriation General Hospital

Enrollment

12 participants

Start Date

Oct 1, 2007

Study Type

Interventional

Conditions

Sports doping detection

Summary

Sports anti doping study. The aim of the study is to obtain specimens of urine and blood from voluneers who have been given an injection of insulin. These samples will then be used to develop tests which will help detect the presence of insulin in the blood and urine of elite athletes who have used insulin illicitly to enhance their performance.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 45 Yearss

Plain Language Summary

Simplified for easier understanding

This is a sports anti-doping study that aims to detect the presence of exogenous (externally administered) insulin in blood and urine samples. The study will collect samples from both type 1 diabetic patients and healthy non-diabetic volunteers who receive an insulin injection. These samples will be used to develop better tests to catch athletes who might illegally use insulin to enhance performance. You may be eligible if: - You are between 18 and 45 years old - You are either a type 1 diabetic already on insulin therapy, OR you are a healthy non-diabetic person (male or female) You may NOT be eligible if (non-diabetic group): - You have coronary artery disease - You have epilepsy - You have diabetes - You are an elite athlete - You are pregnant Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Type I diabetic participants take their usual insulin dose and provide blood and urine samples at baseline and for up to 24 hours. Non diabetic participants are administered intravenous (IV) Actrapid

Type I diabetic participants take their usual insulin dose and provide blood and urine samples at baseline and for up to 24 hours. Non diabetic participants are administered intravenous (IV) Actrapid insulin 0.05iu/kg at visit 1, 70g oral glucose at visit 2 and placebo at visit 3. Blood and urine samples are collected at each visit at baseline then for up to 24 hours. There is a 5 day washout period between visit 1 (insulin administration) and visit 2 (glucose administration). There is no specified washout period between visit 2 and visit 3 (placebo administration).

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12608000237381

Related Trials

Detection of recombinant human luteinising hormone (rLH) as a doping agent

ACTRN126080001813031 location